Section 4 of 6
Clinical evidence
300 evidence topics · 37 sources
Study summaries
EMBARQ-CSU1
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Official title in the ClinicalTrials.gov record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Active, not recruiting” (opens the source at this quote in a new tab)
“Study Start (Actual) 2024-07-11” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-08-12” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-06” (opens the source at this quote in a new tab)
“First Posted 2024-06-06” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-12” (opens the source at this quote in a new tab)
Number of locations and EU trial number in the ClinicalTrials.gov record
Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2
Data cutoff for the topline results
Treatment continuing to 52 weeks with 16 weeks of follow-up
Study design
Study periods in the ClinicalTrials.gov record
Randomization ratio and study periods in the topline presentation
Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release
Placebo for 52 weeks and 16-week follow-up in the Form 10-Q
Timing of the primary endpoint analysis at 24 weeks
Entry into the phase 3b long-term extension after the trial
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
“Women who are pregnant or nursing.” (opens the source at this quote in a new tab)
“Other diseases associated with urticaria.” (opens the source at this quote in a new tab)
“Active pruritic skin condition in addition to CSU.” (opens the source at this quote in a new tab)
“Known HIV, hepatitis B or hepatitis C infection.” (opens the source at this quote in a new tab)
“History of anaphylaxis.” (opens the source at this quote in a new tab)
“Prior treatment with barzolvolimab.” (opens the source at this quote in a new tab)
Population summarized in the topline presentation
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |
Arms with loading doses in the topline presentation
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record
Secondary outcome measures in the current ClinicalTrials.gov record
“Percentage of participants with UAS7 = 0 at Week 12” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)
“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)
“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)
Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history
“Comparing V1 (2024-05-31) to V18 (2026-02-12)” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 4” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 24” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 = 0 at Week 24” (opens the source at this quote in a new tab)
Key secondary endpoints at Week 12 in the topline presentation
Complete response (UAS7=0) as the treatment goal stated by the company
Reason given by the company for presenting complete response at Week 24
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment per trial at initiation
Actual enrollment in the ClinicalTrials.gov record
Participants randomized in the topline release
Description of analysis sets
Adjusted proportions from logistic regression with multiple imputation
Definition of the omalizumab-refractory subpopulation
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
| Characteristic | Placebo every 4 weeks (N=325) | Barzolvolimab 150 mg every 4 weeks (N=320) | Barzolvolimab 300 mg every 8 weeks (N=318) |
|---|---|---|---|
| Age (years), mean (SD) | “46.4 (14.58)” | “46.1 (14.49)” | “47.0 (14.7)” |
| Female, n (%) | “235 (72.3)” | “243 (75.9)” | “228 (71.7)” |
| Race, White, n (%) | “228 (70.2)” | “233 (72.8)” | “216 (67.9)” |
| Race, Black, n (%) | “35 (10.8)” | “39 (12.2)” | “31 (9.7)” |
| Race, Asian, n (%) | “40 (12.3)” | “30 (9.4)” | “47 (14.8)” |
| Weight (kg), mean (SD) | “79.9 (20.47)” | “79.39 (16.98)” | “78.34 (18.06)” |
| UAS7 score, mean (SD) | “30.9 (7.32)” | “30.6 (7.44)” | “30.3 (7.01)” |
| Severe disease (UAS7 of 28 or more), n (%) | “216 (66.5)” | “213 (66.6)” | “216 (67.9)” |
| Omalizumab refractory, n (%) | “55 (16.9)” | “52 (16.3)” | “52 (16.4)” |
| AAS7 greater than 0, n (%) | “237 (72.9)” | “238 (74.4)” | “239 (75.2)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “57.1 (29.99)” | “52.0 (29.15)” | “54.9 (28.24)” |
| DLQI score, mean (SD) | “16.0 (7.34)” | “15.5 (7.13)” | “15.6 (7.13)” |
Efficacy results
Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error
| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
|---|---|---|
| Placebo every 4 weeks | “30.9” | “-10.7 (0.65)” |
| Barzolvolimab 150 mg every 4 weeks | “30.6” | “-20.2 (0.64) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “30.3” | “-20.5 (0.65) (p<.00001)” |
Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set
“Treatment Difference LS Mean (97.5% CI):” (opens the source at this quote in a new tab)
“Full analysis set; imputed data and MMRM model” (opens the source at this quote in a new tab)
| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
|---|---|---|
| Barzolvolimab 150 mg every 4 weeks | “-9.5 (-11.5, -7.4)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-9.8 (-11.9, -7.8)” | “p <.00001” |
Complete response (UAS7=0) at Week 12, adjusted proportions
| Arm | Complete response (UAS7=0) at Week 12 |
|---|---|
| Placebo every 4 weeks | “9.3%” |
| Barzolvolimab 150 mg every 4 weeks | “42.4% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “42.1% (p<.00001)” |
Complete response (UAS7=0) at Week 24 presented by the company
| Arm | Complete response (UAS7=0) at Week 24 |
|---|---|
| Placebo every 4 weeks | “15.4%” |
| Barzolvolimab 150 mg every 4 weeks | “49.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “45.1% (p<.00001)” |
Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants
| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
|---|---|
| Placebo every 4 weeks | “9.3%” |
| Barzolvolimab 150 mg every 4 weeks | “55.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.3% (p=.00017)” |
AAS7=0 at Week 12 in participants with baseline AAS7>0
| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
|---|---|
| Placebo every 4 weeks | “33.8%” |
| Barzolvolimab 150 mg every 4 weeks | “62.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.3% (p<.00001)” |
Other key secondary endpoints at Week 12 reported as met without values
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety statement through the 24-week placebo-controlled period
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
|---|---|---|---|
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |
Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
“AG3 anaphylaxis adjudicated as unlikely” (opens the source at this quote in a new tab)
“BG2 angioedema/throat tightness/urticaria” (opens the source at this quote in a new tab)
“CG3 anemia/neutropenia;” (opens the source at this quote in a new tab)
“G2 malaise/dyspnea/chest pain;” (opens the source at this quote in a new tab)
Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Study limitations
Summary: limitations of the available EMBARQ-CSU1 evidence
- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-05-31) with version 18 (2026-02-12) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (15.4%, 49.0%, and 45.1%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24. The sources state the placebo duration differently: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 16.0, 15.5, and 15.6), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 55, 52, and 52 participants (16.9%, 16.3%, and 16.4% of each arm). The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.
EMBARQ-CSU2
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Official title in the ClinicalTrials.gov record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Active, not recruiting” (opens the source at this quote in a new tab)
“Study Start (Actual) 2024-07-19” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-08-04” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-06” (opens the source at this quote in a new tab)
“First Posted 2024-06-12” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-12” (opens the source at this quote in a new tab)
Number of locations and EU trial number in the ClinicalTrials.gov record
Completion of enrollment in February 2026 and countries and sites across EMBARQ-CSU1 and EMBARQ-CSU2
Data cutoff for the topline results
Treatment continuing to 52 weeks with 16 weeks of follow-up
Study design
Study periods in the ClinicalTrials.gov record
Randomization ratio and study periods in the topline presentation
Randomization, placebo period of 24 weeks, and re-randomization of placebo participants in the topline release
Placebo for 52 weeks and 16-week follow-up in the Form 10-Q
Timing of the primary endpoint analysis at 24 weeks
Entry into the phase 3b long-term extension after the trial
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
“Women who are pregnant or nursing.” (opens the source at this quote in a new tab)
“Other diseases associated with urticaria.” (opens the source at this quote in a new tab)
“Active pruritic skin condition in addition to CSU.” (opens the source at this quote in a new tab)
“Known HIV, hepatitis B or hepatitis C infection.” (opens the source at this quote in a new tab)
“History of anaphylaxis” (opens the source at this quote in a new tab)
“Prior treatment with barzolvolimab” (opens the source at this quote in a new tab)
Population summarized in the topline presentation
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Barzolvolimab 150 mg | “barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Placebo intervention | “Matching placebo Subcutaneous Administration” |
Arms with loading doses in the topline presentation
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Primary endpoint and definition of the UAS7 in the ClinicalTrials.gov record
Secondary outcome measures in the current ClinicalTrials.gov record
“Percentage of patients with UAS7=0 at Week 12” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)
“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)
“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)
Secondary outcome amendment of February 2026: version 1 compared with version 18 in the record history
“Comparing V1 (2024-06-07) to V18 (2026-02-03)” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 4” (opens the source at this quote in a new tab)
“Mean change from baseline in UAS7 at Week 24” (opens the source at this quote in a new tab)
“Percentage of participants with UAS7 = 0 at Week 24” (opens the source at this quote in a new tab)
Key secondary endpoints at Week 12 in the topline presentation
Complete response (UAS7=0) as the treatment goal stated by the company
Reason given by the company for presenting complete response at Week 24
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment per trial at initiation
Actual enrollment in the ClinicalTrials.gov record
Participants randomized in the topline release
Description of analysis sets
Adjusted proportions from logistic regression with multiple imputation
Definition of the omalizumab-refractory subpopulation
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
| Characteristic | Placebo every 4 weeks (N=321) | Barzolvolimab 150 mg every 4 weeks (N=324) | Barzolvolimab 300 mg every 8 weeks (N=321) |
|---|---|---|---|
| Age (years), mean (SD) | “45.7 (14.59)” | “46.2 (14.53)” | “46.2 (14.01)” |
| Female, n (%) | “215 (67.0)” | “229 (70.7)” | “208 (64.8)” |
| Race, White, n (%) | “229 (71.3)” | “225 (69.4)” | “242 (75.4)” |
| Race, Black, n (%) | “6 (1.9)” | “11 (3.4)” | “8 (2.5)” |
| Race, Asian, n (%) | “49 (15.3)” | “54 (16.7)” | “50 (15.6)” |
| Weight (kg), mean (SD) | “80.70 (18.96)” | “78.72 (19.10)” | “79.94 (19.15)” |
| UAS7 score, mean (SD) | “29.3 (7.19)” | “29.7 (6.87)” | “29.6 (7.28)” |
| Severe disease (UAS7 of 28 or more), n (%) | “199 (62.0)” | “203 (62.7)” | “198 (61.7)” |
| Omalizumab refractory, n (%) | “43 (13.4)” | “44 (13.6)” | “42 (13.1)” |
| AAS7 greater than 0, n (%) | “206 (64.2)” | “213 (65.7)” | “217 (67.6)” |
| AAS7 in participants with AAS7 greater than 0, mean (SD) | “50.2 (28.63)” | “51.5 (28.67)” | “51.7 (27.81)” |
| DLQI score, mean (SD) | “14.2 (7.11)” | “14.4 (7.02)” | “14.3 (7.11)” |
Efficacy results
Primary endpoint: LS mean change from baseline in UAS7 at Week 12 with standard error
| Arm | Baseline UAS7 | LS mean change (SE) at Week 12 |
|---|---|---|
| Placebo every 4 weeks | “29.3” | “-11.4 (0.64)” |
| Barzolvolimab 150 mg every 4 weeks | “29.7” | “-20.2 (0.63) (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “29.6” | “-19.7 (0.64) (p<.00001)” |
Primary endpoint: treatment difference in UAS7 change at Week 12 with 97.5% CI, full analysis set
“Treatment Difference LS Mean (97.5% CI):” (opens the source at this quote in a new tab)
“Full analysis set; imputed data and MMRM model” (opens the source at this quote in a new tab)
| Comparison with placebo | Treatment difference, LS mean (97.5% CI) | P-value |
|---|---|---|
| Barzolvolimab 150 mg every 4 weeks | “-8.9 ( -10.9, -6.9)” | “p <.00001” |
| Barzolvolimab 300 mg every 8 weeks | “-8.3 ( -10.4, -6.3)” | “p < .00001” |
Complete response (UAS7=0) at Week 12, adjusted proportions
| Arm | Complete response (UAS7=0) at Week 12 |
|---|---|
| Placebo every 4 weeks | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “45.7% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “44.0% (p<.00001)” |
Complete response (UAS7=0) at Week 24 presented by the company
| Arm | Complete response (UAS7=0) at Week 24 |
|---|---|
| Placebo every 4 weeks | “17.6%” |
| Barzolvolimab 150 mg every 4 weeks | “54.0% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “48.4% (p<.00001)” |
Complete response (UAS7=0) at Week 12 in omalizumab-refractory participants
| Arm | Complete response (UAS7=0) at Week 12, omalizumab refractory |
|---|---|
| Placebo every 4 weeks | “15.1%” |
| Barzolvolimab 150 mg every 4 weeks | “41.7% (p=.0089)” |
| Barzolvolimab 300 mg every 8 weeks | “46.4% (p=.0036)” |
AAS7=0 at Week 12 in participants with baseline AAS7>0
| Arm | AAS7=0 at Week 12, baseline AAS7 greater than 0 |
|---|---|
| Placebo every 4 weeks | “33.7%” |
| Barzolvolimab 150 mg every 4 weeks | “74.3% (p<.00001)” |
| Barzolvolimab 300 mg every 8 weeks | “66.2% (p<.00001)” |
Other key secondary endpoints at Week 12 reported as met without values
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety statement through the 24-week placebo-controlled period
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
| Event, N (%) | Placebo every 4 weeks (N=645) | Barzolvolimab 150 mg every 4 weeks (N=648) | Barzolvolimab 300 mg every 8 weeks (N=641) |
|---|---|---|---|
| Participants with at least 1 adverse event | “340 (52.7)” | “490 (75.6)” | “492 (76.8)” |
| Hair color changes | “29 (4.5)” | “292 (45.1)” | “330 (51.5)” |
| Skin hypopigmentation | “16 (2.5)” | “71 (11.0)” | “64 (10.0)” |
| Neutropenia | “4 (0.6)” | “59 (9.1)” | “75 (11.7)” |
| Skin hyperpigmentation | “5 (0.8)” | “59 (9.1)” | “58 (9.1)” |
| Dysgeusia | “9 (1.4)” | “44 (6.8)” | “63 (9.8)” |
| Hypogeusia | “10 (1.6)” | “33 (5.1)” | “53 (8.3)” |
| Nasopharyngitis | “36 (5.6)” | “41 (6.3)” | “40 (6.2)” |
| Anemia | “4 (0.6)” | “20 (3.1)” | “20 (3.1)” |
| Participants with serious adverse events | “15 (2.3)” | “6 (0.9)” | “14 (2.2)” |
| Treatment-related serious adverse events | “1 (0.2)” | “3 (0.5)” | “4 (0.6)” |
| Anaphylaxis adjudicated as probable (grade 4) | “0” | “2” | “1 (occurred after placebo dose)” |
| Anaphylaxis, other | “1A” | “1B” | “3C” |
Footnotes to the other anaphylaxis events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
“AG3 anaphylaxis adjudicated as unlikely” (opens the source at this quote in a new tab)
“BG2 angioedema/throat tightness/urticaria” (opens the source at this quote in a new tab)
“CG3 anemia/neutropenia;” (opens the source at this quote in a new tab)
“G2 malaise/dyspnea/chest pain;” (opens the source at this quote in a new tab)
Severity and serious adverse events, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Infections and neutropenia, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Study limitations
Summary: limitations of the available EMBARQ-CSU2 evidence
- Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
- The record history comparing version 1 (2024-06-07) with version 18 (2026-02-03) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (17.6%, 54.0%, and 48.4%) are presented by the company, which cites the importance of complete response to patients and physicians.
- Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
- Participant counts are reported from different sources without reconciliation: 976 participants randomized (release) and enrolled (ClinicalTrials.gov), and a full analysis set of N=321, N=324, and N=321 by arm (presentation). The placebo duration also differs: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”. Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24.
- Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
- Baseline DLQI is reported (mean 14.2, 14.4, and 14.3), but no DLQI or other health-related quality of life result after baseline is reported.
- The omalizumab-refractory subpopulation comprised 43, 44, and 42 participants (13.4%, 13.6%, and 13.1% of each arm), with p-values of .0089 and .0036 for UAS7=0 at Week 12 in this subgroup. The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.
CDX0159-17
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Time to disease worsening as the aim in the detailed description
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Enrolling by invitation” (opens the source at this quote in a new tab)
“Study Start (Actual) 2025-11-25” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-09” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2028-09” (opens the source at this quote in a new tab)
“First Posted 2025-12-01” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-02” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Long-term extension established and ongoing at the phase 3 topline
Study design
Observation and retreatment groups assigned by UAS7 at entry, and duration of participation
Observation and retreatment groups described in the Form 10-Q
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Treatment
Groups and interventions in the ClinicalTrials.gov record
| Group | Description in the record |
|---|---|
| Group 1, observation | “Standard of care treatment (at least 2nd generation Type 1 antihistamines [H1AH] with or without other permitted background medications) for 52 weeks.” |
| Group 1, rescue for worsening disease | “For participants with worsening disease (UAS7 score of 16 or greater at any time between Weeks 0-24), barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
| Group 2, retreatment | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Standard of care intervention | “Observational/Standard of Care” |
Treatment of observation group participants whose disease flares in the first 6 months
Study outcomes
Rationale for using time to disease worsening as the primary endpoint
Primary outcome measures in the ClinicalTrials.gov record
Definition of the UAS7 in the ClinicalTrials.gov record
Secondary outcome measures for the observation group (Group 1)
Secondary outcome measures for the retreatment group (Group 2)
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations of the available long-term extension evidence
- The phase 3b long-term extension (NCT07256392) started 2025-11-25, is enrolling by invitation, and has an estimated primary completion of 2028-09. No disposition, baseline, efficacy, quality of life, or safety results have been reported.
- The design is non-randomized and open label. Participants are assigned by UAS7 at entry: those with UAS7 below 16 enter an observation group on standard of care (at least second-generation H1 antihistamines), and those with UAS7 of 16 or greater enter a barzolvolimab retreatment group.
- Retreatment and rescue of observation-group participants with worsening disease both use a 300 mg loading dose followed by 150 mg every 4 weeks; the 300 mg every 8 weeks regimen of the phase 3 trials is not among the extension's interventions.
- Enrollment is limited to participants who completed the preceding phase 3 trials (CDX0159-12 or CDX0159-13) and have at least one documented UAS7 score from Weeks 64 to 68 of those trials.
- The primary endpoint is time to disease worsening or treatment failure through Week 52, defined by UAS7 of 16 or greater, discontinuation of barzolvolimab in the retreatment group for lack of efficacy or a treatment-related adverse event, or first use of a strongly confounding prohibited medication or of barzolvolimab in the observation group. Estimated enrollment is 1370.
CDX0159-06
Objective
Objective stated in the primary publication
Dose-finding purpose stated by the company
Objectives of the Week 52, follow-up, and off-treatment analyses
Location and study date
Number of locations in the ClinicalTrials.gov record
Screening dates, last Week 12 visit, and regions in the primary publication
Sites and countries stated by the company: 9 countries
Sites and countries in the 52-week presentation: 10 countries
First participant dosed, June 2022
Interim data cut for the 52-week analysis
Study design
Design in the ClinicalTrials.gov record
Study periods, randomization ratio, and stratification in the primary publication
Blinding and unblinded pharmacist
Dose selection based on healthy volunteer modeling
Re-randomization at Week 16 and off-treatment follow-up
Clinic visits and diaries in each period
Design stated by the company
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
“Women who are pregnant or nursing.” (opens the source at this quote in a new tab)
“Clearly defined cause for chronic urticaria.” (opens the source at this quote in a new tab)
“Active, pruritic skin condition in addition to CSU.” (opens the source at this quote in a new tab)
“History of anaphylaxis” (opens the source at this quote in a new tab)
“Prior treatment with barzolvolimab” (opens the source at this quote in a new tab)
Eligibility in the primary publication, including antihistamine dose and hematology criteria
Biologic washout and prior omalizumab in the primary publication
Population described in the congress presentations, including prior biologics
Treatment
Arms in the ClinicalTrials.gov record
| Arm | Description |
|---|---|
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
Dosing schedule with placebo injections in the every-8-weeks group
Rescue antihistamine and oral corticosteroids
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Primary endpoint and UAS7 definition in the ClinicalTrials.gov record
Secondary endpoints in the ClinicalTrials.gov record: ISS7, HSS7, and AAS7
Complete response as the treatment goal, and UAS7 disease activity categories
Secondary and exploratory endpoints in the primary publication, including CSU-free status
UAS7 health states used for the Week 52 to Week 76 follow-up
Angioedema Activity Score over 7 days: range and dimensions
AAS7 improvement of more than 8 points as the clinically meaningful threshold
Urticaria Control Test and Dermatology Life Quality Index: ranges and thresholds
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power in the primary publication
Planned enrollment stated at the first dose, June 2022
Actual enrollment in the ClinicalTrials.gov record
Participants screened, randomized, treated, and completing Week 12
Participants per randomized group in the primary publication
Participants treated and entering the 24-week follow-up period
Participants in the post hoc off-treatment analysis
Participants in the angioedema subgroup
Participants in the pigmentation analysis
Participants in the baseline IgE subgroup analysis
Description of analysis sets
Modified intent-to-treat and safety populations
Handling of missing daily diary scores
Week 12 primary analysis: analysis of covariance with multiple imputation and Benjamini-Hochberg adjustment
Congress presentations: modified intent to treat and as-observed analyses
Pooled dose groups in the safety tables of the congress presentation
Post hoc subgroup analyses by baseline IgE and baseline serum tryptase
Results
Participant disposition
Disposition through Week 12
Treatment discontinuations through Week 52 by randomized group
| Reason | 75 mg every 4 weeks, then 150 or 300 mg | 150 mg every 4 weeks | 300 mg every 8 weeks | Placebo, then 150 or 300 mg |
|---|---|---|---|---|
| Group size | “(n=53)” | “(n=52)” | “(n=52)” | “(n=51)” |
| Discontinued treatment, n (%) | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
| Patient decision | “1 (2%)” | “3 (6%)” | “1 (2%)” | “3 (6%)” |
| Non-compliance | “2 (4%)” | “1 (2%)” | “1 (2%)” | “2 (4%)” |
| Lack of clinical response | “1 (2%)” | “0” | “2 (4%)” | “1 (2%)” |
| Other | “2 (4%)” | “5 (10%)” | “2 (4%)” | “0” |
Discontinuations during the 16-week placebo-controlled period and adverse events leading to discontinuation
Participants treated and entering the follow-up period
Baseline characteristics
Demographics and baseline disease characteristics by randomized group
Baseline imbalances in the 300 mg every 8 weeks group
Baseline AAS7 in participants with angioedema at baseline
Baseline UCT and DLQI in the 150 mg and 300 mg groups
Baseline characteristics of participants with well-controlled disease at Week 52
Efficacy results
Week 12 primary endpoint: UAS7 change from baseline versus placebo
Week 12 efficacy endpoints by randomized group
| Endpoint at Week 12 | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
|---|---|---|---|---|
| UAS7 LS mean change from baseline (SE) | “−17.06 (1.493)” | “−23.02 (1.416)” | “−23.87 (1.479)” | “−10.47 (1.462)” |
| UAS7 treatment difference vs placebo (95% CI) | “−6.60 (−10.71, −2.49)” | “−12.55 (−16.56, −8.55)” | “−13.41 (−17.47, −9.34)” | Not applicable |
| ISS7 LS mean change from baseline (SE) | “−8.62 (0.794)” | “−11.68 (0.766)” | “−11.79 (0.788)” | “−5.47 (0.784)” |
| ISS7 treatment difference vs placebo (95% CI) | “−3.16 (−5.41, −0.91)” | “−6.21 (−8.38, −4.04)” | “−6.32 (−8.50, −4.13)” | Not applicable |
| HSS7 LS mean change from baseline (SE) | “−8.25 (0.747)” | “−11.19 (0.750)” | “−12.19 (0.745)” | “−4.95 (0.772)” |
| HSS7 treatment difference vs placebo (95% CI) | “−3.31 (−5.40, −1.22)” | “−6.24 (−8.33, −4.16)” | “−7.24 (−9.36, −5.12)” | Not applicable |
| AAS7 LS mean change from baseline (SE) | “−24.10 (2.831)” | “−27.99 (2.815)” | “−29.95 (2.843)” | “−12.56 (3.056)” |
| AAS7 treatment difference vs placebo (95% CI) | “−11.55 (−20.04, −3.05)” | “−15.43 (−23.52, −7.34)” | “−17.39 (−25.49, −9.30)” | Not applicable |
| Well-controlled disease (UAS7 ≤ 6) (%) | “41.7” | “59.6” | “62.5” | “12.8” |
| UAS7 ≤ 6 difference in proportions vs placebo (95% CI) | “0.29 (0.12, 0.46)” | “0.47 (0.3, 0.64)” | “0.50 (0.33, 0.66)” | Not applicable |
| Complete control (UAS7 = 0) (%) | “22.9” | “51.1” | “37.5” | “6.4” |
| UAS7 = 0 difference in proportions vs placebo (95% CI) | “0.17 (0.03, 0.3)” | “0.45 (0.29, 0.61)” | “0.31 (0.16, 0.46)” | Not applicable |
| CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%) | “19.2” | “50.0” | “33.3” | “5.9” |
Week 12 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) versus placebo
Week 12 angioedema activity (AAS7) in participants with angioedema at baseline
Week 12 AAS7 improvement of more than 8 points and angioedema-free days
| Measure at Week 12 (participants with angioedema at baseline) | 300 mg every 8 weeks | 150 mg every 4 weeks | 75 mg every 4 weeks | Placebo |
|---|---|---|---|---|
| Angioedema at baseline, n (%) | “42 (82%)” | “35 (67%)” | “40 (75%)” | “32 (63%)” |
| Baseline AAS7 (mean) | “53.15” | “54.60” | “54.05” | “56.30” |
| >8 point improvement in AAS7 (%) | “85.0” | “87.1” | “82.9” | “57.1” |
| Angioedema free days (mean) | “65.1” | “54.5” | “43.3” | “36.2” |
Week 12 serum tryptase reduction
Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16
Week 52 response stated by the company and by prior omalizumab experience
Week 52 angioedema activity (AAS7) in participants with angioedema at baseline
Week 52 and Week 76 AAS7 change and angioedema-free status (AAS7 = 0) across the four groups
Week 12 and Week 52 efficacy by baseline IgE
Week 12 and Week 52 efficacy by baseline serum tryptase
Week 76, 28 weeks after the last dose: UAS7 change, UAS7 = 0, and UAS7 ≤ 6
“UAS7 Mean CFB (SE) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was -20.4 (2.5)” (opens the source at this quote in a new tab)
“300 mg Q8W was -21.1 (1.9)” (opens the source at this quote in a new tab)
“UAS7=0 (%) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was 41%” (opens the source at this quote in a new tab)
“300 mg Q8W was 35%” (opens the source at this quote in a new tab)
“UAS7≤6 (%) at W76” (opens the source at this quote in a new tab)
“150 mg Q4W was 56%” (opens the source at this quote in a new tab)
“300 mg Q8W was 47%” (opens the source at this quote in a new tab)
“Modified intent to treat; observed data.” (opens the source at this quote in a new tab)
Week 76 in participants with well-controlled disease (UAS7 ≤ 6) at Week 52
Week 76 disease severity at recurrence after treatment completion
Health-related quality of life and patient-reported outcomes
Week 12 Urticaria Control Test (UCT7): treatment differences versus placebo
Well-controlled urticaria (UCT7 ≥ 12) at 12 and 52 weeks and 28 weeks after the last dose
Week 52 UCT and DLQI change from baseline in the 150 mg and 300 mg groups
Week 52 DLQI 0 or 1, DLQI improvement, and UCT control stated by the company
Week 76 DLQI 0 or 1
Week 76 DLQI in participants with well-controlled disease (UAS7 ≤ 6) at Week 52
Week 52 and Week 76 DLQI in the post hoc quality of life analysis
Safety results
Baseline through Week 12: adverse events, serious adverse events, and discontinuations
| Event | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Pooled barzolvolimab (n = 156) | Placebo (n = 51) |
|---|---|---|---|---|---|
| Patients with ≥1 TEAE | “28 (52.8)” | “29 (55.8)” | “31 (60.8)” | “88 (56.4)” | “14 (27.5)” |
| Patients with serious AE | “0” | “0” | “1 (2.0)” | “1 (0.6)” | “0” |
| Discontinued study treatment due to TEAE | “2 (3.8)” | “1 (1.9)” | “4 (7.8)” | “7 (4.5)” | “0” |
| Hair color changes | “0” | “5 (9.6)” | “9 (17.6)” | “14 (9.0)” | “0” |
| Urticaria/CSU | “8 (15.1)” | “5 (9.6)” | “3 (5.9)” | “16 (10.3)” | “5 (9.8)” |
| Neutropenia (neutropenia and neutrophil count decreased) | “4 (7.6)” | “3 (5.7)” | “5 (9.8)” | “12 (7.7)” | “0” |
Week 12 neutropenia: onset, duration, and infections
Week 16 placebo-controlled period and Week 52 full treatment period: adverse events
| Patients, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 (N= 156) | Placebo, Weeks 0 to 16 (N= 51) | Barzolvolimab, all doses, Weeks 0 to 52 (N= 156) | Placebo then barzolvolimab, 36 weeks (N=48) |
|---|---|---|---|---|
| At least one AE | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment related SAEs | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia / neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |
“Placebo Controlled Period (16 weeks)” (opens the source at this quote in a new tab)
“Full Treatment Period (52 weeks)” (opens the source at this quote in a new tab)
“4 SAEs of worsening urticaria symptoms” (opens the source at this quote in a new tab)
“Adverse events were not dose dependent” (opens the source at this quote in a new tab)
Week 52 neutrophil counts and skin hypopigmentation stated by the company
Follow-up period through 76 weeks: neutrophil recovery and reversibility of pigment changes
Hair color and skin pigmentation changes over 76 weeks: incidence, onset, severity, and resolution
Limitations of the pigmentation photography stated by the authors
Study limitations
Summary
- Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
- Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
- Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
- Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
- Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
- Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
- Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
- Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
- Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
- Immunogenicity: no antidrug antibody results from this study were found.
- Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.
CDX0159-02
Objective
Primary objective: safety of multiple doses
“The main objective of the trial was to evaluate the barzolvolimab MAD safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary objectives: pharmacokinetics, disease activity, tryptase, SCF, and immunogenicity
“The secondary objectives were to characterize the barzolvolimab MAD PK profile; PD effect (UAS7, HSS7, itch severity score [ISS7], and urticaria control test [UCT]); tryptase and SCF levels; and immunogenicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry purpose: safety, pharmacodynamics, and pharmacokinetics in antihistamine-refractory CSU
Location and study date
Registry dates and study sites in the United States and Germany
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-09-24” |
| Primary completion (actual) | “2023-01-17” |
| Study completion (actual) | “2023-01-17” |
| Countries of listed sites | “United States”; “Germany” |
| Site in Germany | “Charite University” |
First participant dosed, October 2020
Study completion reported in June 2023
Study design
Randomized, double-blind, placebo-controlled design with screening, treatment, and follow-up periods
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included the following periods: 2‐week screening, 12‐week treatment, and 12‐week posttreatment follow‐up (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Four sequentially enrolled intravenous cohorts randomized 4:1
Registry title: phase 1 multiple ascending dose add-on study
Dose and schedule selection from the single-dose healthy-volunteer study
“Doses were selected based on results from the single‐dose healthy‐volunteer study [10], in which 0.3–9 mg/kg barzolvolimab was well tolerated and demonstrated dose‐dependent suppression of serum tryptase (Supporting Information Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in design, data analysis, and manuscript preparation
“This trial was designed and sponsored by Celldex Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data were collected by the trial investigators according to Good Clinical Practice guidelines and were analyzed by the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first draft of the manuscript was written by a medical writer paid by the sponsor, with critical input and approval from all authors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, disease activity, disease duration, and antihistamine use
“Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: recent biologics, prior barzolvolimab, immunosuppressives, oral doxepin, and other itching skin disease
“Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior biologic treatment permitted with washout
Registry criteria: blood counts, contraception for 150 days, live vaccines, pregnancy, and anaphylaxis
Treatment
Intravenous infusion every 4 or 8 weeks as add-on to antihistamines
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry arms: CDX-0159 or normal saline every 4 to 8 weeks
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Registry primary outcome: incidence and severity of adverse events to Day 169
Safety assessments
“Safety was assessed by the incidence and severity of treatment‐emergent adverse events (TEAEs) and serious AEs (SAEs), dose‐limiting toxicities, clinical laboratory tests, vital sign measurements, 12‐lead electrocardiograms, and physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale: first multiple-dose study after single-dose studies
“We report the effect of multiple ascending doses (MAD) of barzolvolimab on safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and clinical activity in CSU patients whose disease is inadequately controlled by antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry secondary outcomes: pharmacokinetics, UAS7, HSS7, ISS7, UCT, stem cell factor, tryptase, and immunogenicity
Weekly urticaria activity score (UAS7): components, range 0 to 42, and disease activity categories
Urticaria Control Test (UCT): range 0 to 16, complete control at 16, well controlled at 12 or more
Assessment ranges for UAS7, AAS7, UCT, and DLQI
Physician Global Assessment (PhysGA): range 0 to 3
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: approximately 40 participants in four cohorts
Participants by cohort
“0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All barzolvolimab (N = 35)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled placebo (N = 10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interim analysis population, May 2022 data cutoff
Analysis population, November 2022 data cutoff
Description of analysis sets
Safety population: all participants who received at least one dose
Analysis by dose with placebo pooled across cohorts
“Results were analyzed by dose and overall for patients who received barzolvolimab. The placebo group was pooled from each cohort. Baseline was defined as the last available measurement prior to study treatment administration. Change from baseline was calculated as the difference between postbaseline and baseline values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Safety was assessed separately by treatment group and as pooled active treatment. Analyses included the number and percentage of patients experiencing AEs, summarized by severity and relationship to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive pharmacokinetic, antidrug antibody, and pharmacodynamic analyses
“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings. The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively. Summary statistics were descriptive and presented to evaluate PD changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis set and data included at the November 2022 data cutoff
Company responder analyses: participants with missing data excluded, Week 24 shown only where at least 50% had data
Results
Participant disposition
Completion of the 12-week treatment period
“Overall, 42 patients (93.3%) completed treatment (Figure S2). Three patients did not complete the treatment period: one in the barzolvolimab 4.5‐mg/kg group because of low white blood count (WBC), and two in the placebo group who sought alternate treatment for CSU because of symptom severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses not received and follow-up discontinuation, November 2022 data cutoff
Baseline characteristics
Demographics and baseline disease characteristics by cohort
Disease severity, prior omalizumab and biologic use, and angioedema history
“Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority had an inadequate response to omalizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no notable differences between the barzolvolimab and placebo groups in the demographic or clinical characteristics at baseline (Table 1). Most patients had severe disease per UAS7. A total of 44% of patients had prior use of biologics. The percentage of patients with a history of angioedema was similar between placebo (50%) and across the barzolvolimab groups (60%), with mean baseline angioedema activity score over 7 days (AAS7) of 26.6 and 26.0, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff
| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| Race, White, n (%) | “6 (67)” | “7 (88)” | “9 (100)” | “7 (78)” | “29 (83)” | “7 (70)” |
| Race, African American, n (%) | “3 (33)” | “1 (13)” | “0 (0)” | “1 (11)” | “5 (14)” | “3 (30)” |
| Race, Other, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (11)” | “1 (3)” | “0 (0)” |
| Prior angioedema, n (%) | “5 (56)” | “5 (63)” | “5 (56)” | “6 (67)” | “21 (60)” | “5 (50)” |
| ISS7, mean (range) | “15.7 (11.0 - 21.0)” | “15.5 (12.0 - 21.0)” | “14.6 (1.2 - 21.0)” | “15.4 (10.5 -19.0)” | “15.3 (1.2 - 21.0)” | “19.3 (12.0 - 21.0)” |
| HSS7, mean (range) | “15.4 (8.0 - 21.0)” | “14.0 (8.0 - 21.0)” | “14.8 (8.0 - 21.0)” | “12.4 (7.0 -19.0)” | “14.1 (7.0 - 21.0)” | “16.5 (7.0 - 21.0)” |
| UAS7, mean (range) | “31.1 (20.0 - 39.0)” | “29.4 (20.0 - 40.6)” | “29.4 (16.3 - 42.0)” | “27.8 (17.5 - 38.0)” | “29.4 (16.3 - 42.0)” | “35.8 (19.0 - 42.0)” |
| Total IgE, kU/L, mean (range) | “80 (2 - 239)” | “161 (13 - 328)” | “337 (4 - 1371)” | “88 (2 - 307)” | “165 (2 - 1371)” | “161 (5 - 409)” |
Baseline DLQI and PhysGA by cohort
| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| DLQI, mean (range) | “13.2 (7-24)” | “15.1 (5-24)” | “7.8 (1-15)” | “9.7 (1-16)” | “11.3 (1-24)” | “13.5 (1-26)” |
| PhysGA, mean (range) | “1.9 (1-3)” | “2.3 (1-3)” | “2.7 (2-3)” | “2.1 (1-3)” | “2.2 (1-3)” | “2.1 (1-3)” |
Prior omalizumab use in interim company reports, May 2022 and November 2022 data cutoffs
Efficacy results
Week 12 UAS7 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6), all barzolvolimab doses versus placebo
“UAS7 response to barzolvolimab was greater than placebo: 71.4% of barzolvolimab‐treated patients had a well‐controlled response (UAS7 ≤ 6) by Week 12, compared with 30.0% of placebo‐treated patients (Figure 1C), and 57.1% of barzolvolimab‐treated patients had a complete response (UAS7 = 0) by Week 12 compared with 20% of placebo‐treated patients (Figure 1D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 UCT well-controlled disease (UCT ≥ 12) and complete response (UCT = 16), all barzolvolimab doses
UAS7, HSS7, ISS7, and UCT change from baseline from Week 1 through Week 24
“Urticaria symptoms measured by change from baseline in UAS7 improved by Week 1 (Figure 1A) for all barzolvolimab dose levels compared with placebo. Sustained improvement of UAS7 scores through Week 24 was seen for the groups ≥ 1.5 mg/kg. HSS7 and ISS7, the two components of UAS7 score, showed comparable improvement in each urticaria symptom measurement by Week 1 and sustained improvement of scores through Week 24 for the ≥ 1.5‐mg/kg groups (Figure S4). Sustained improvement was also observed by change from baseline in UCT (Figure 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 24 urticaria-free status (UAS7 = 0) at doses of 1.5 mg/kg or more, 16 weeks after the last dose
Transient response at the lowest dose (0.5 mg/kg)
Prior omalizumab subgroup: Week 12 UAS7 = 0 and UAS7 ≤ 6, pooled doses of 1.5 mg/kg or more
“A subgroup analysis of patients who had previously received omalizumab had a similar response profile (UAS7 and UCT) to those who were naive to omalizumab (Figure 3); the majority of experienced patients had discontinued prior omalizumab because of a lack of symptom control. Doses ≥ 1.5 mg/kg were pooled in barzolvolimab‐treated patients, and a complete response (UAS7 = 0) and well‐controlled response (UAS7 ≤ 6) by Week 12 were observed in 53.8% and 84.6% of barzolvolimab‐treated patients with prior omalizumab treatment, respectively, which is similar to the overall group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Authors' comparison with omalizumab registrational trials at Week 12
“A total of 71% of barzolvolimab‐treated patients across doses achieved a well‐controlled (UAS7 ≤ 6) response, and 57% of the patients achieved a complete response (UAS7 = 0) during the first 12 weeks (compared with 36% of participants treated with omalizumab 300 mg Q4W in registrational trials at 12 weeks [12]); this was sustained through Week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled doses of 1.5 mg/kg or more: UAS7 = 0 and UAS7 ≤ 6 at Weeks 12 and 24
“56% of patients at Week 12” (opens the source at this quote in a new tab)
“55% of patients at Week 24” (opens the source at this quote in a new tab)
“Well controlled Urticaria at doses ≥ 1.5 mg/kg:” (opens the source at this quote in a new tab)
“64% of patients at Week 12” (opens the source at this quote in a new tab)
“60% of patients at Week 24” (opens the source at this quote in a new tab)
“Well Controlled Urticaria UAS7 ≤ 6” (opens the source at this quote in a new tab)
Week 12 UAS7 and UCT by cohort, November 2022 data cutoff
Pooled doses of 1.5 mg/kg or more: UAS7 = 0 at Weeks 12 and 20, November 2022 data cutoff
Week 24 UAS7 and UCT by cohort, complete 24-week data
Week 24 maintenance of a Week 12 complete response (UAS7 = 0), doses of 1.5 mg/kg or more
Interim Week 8 and Week 12 UAS7 and UCT results, May 2022 data cutoff
Angioedema: AAS7 improvement and angioedema-free participants (AAS7 = 0) at Weeks 12 and 24
Physician Global Assessment (PhysGA) from Week 1 through Week 24
“Physician Global Assessment (PhysGA) showed decreases starting at Week 1 (mean baseline score for pooled barzolvolimab group = 2.2 vs. 0.6 [Week 1]), which were sustained through Week 24 (Week 24 = 0.8 [1.5 mg/kg], 0.4 [3.0 mg/kg], and 0.6 [4.5 mg/kg]; Figure S6B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics: exposure through 24 weeks and dose-linear Cmax and AUC
“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A). Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1). Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics: serum tryptase suppression and plasma SCF increase
“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B). Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation. Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
DLQI through Week 24 at doses of 1.5 mg/kg or more
“Decreases in the Dermatology Life Quality Index (DLQI) mean scores for the ≥ 1.5‐mg/kg barzolvolimab groups were sustained through Week 24 (baseline score = 11.3 in pooled barzolvolimab group vs. Week 24 mean scores = 1.3 [1.5 mg/kg], 3.2 [3.0 mg/kg], and 2.0 [4.5 mg/kg]; Figure S6A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The increased symptom control observed with barzolvolimab was reflected in the quality of life measurements, which showed profound improvement between Weeks 1 and 4 that was sustained through Week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DLQI decrease within 4 weeks in all barzolvolimab groups
Safety results
Treatment-emergent adverse events through 24 weeks: incidence, infusion-related events, interruptions, and discontinuations
“Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate in severity and resolved while on study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks
Hair color changes: locations and resolution
“Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections and their relation to neutrophil decreases
“A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse event: grade 4 salmonella gastroenteritis assessed as unrelated
“One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hematologic decreases after the first dose and grade 3 shifts
“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in 57% without apparent effect on exposure or safety
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in 51%, November 2022 data cutoff
KIT-mediated adverse events and expected recovery after drug clearance
“The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition. The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff
| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| Any AE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “5 (50)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “4 (44)” | “8 (23)” | “0 (0)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1(11)” | “5 (14)” | “1 (10)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “2 (25)” | “2 (22)” | “0 (0)” | “5 (14)” | “0 (0)” |
Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster
Interim safety, May 2022 data cutoff
Neutrophil decreases reported as adverse events and hematologic recovery, November 2022 data cutoff
Study limitations
Summary
- Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
- Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
- Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
- Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
- Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
- Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
- Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
- Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
- Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
- Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
- Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
- Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
- The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
- Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
- External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.